Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!
Human respiratory syncytial virus is a highly infectious member of the pulmonary virus family of negative envelope RNA viruses. Over 80% of the population has been exposed to respiratory syncytial virus by the age of 2 years, making respiratory syncytial virus the most common cause of acute lower respiratory illness in children under 5 years of age who are hospitalised. Currently, the only respiratory syncytial virus approved intervention to reduce respiratory syncytial virus-related hospitalisation in young infants is the prophylactic administration of the monoclonal antibody (mAb) palivizumab. Although several respiratory syncytial virus vaccine programmes have been in clinical development over the past decade, no vaccine has been approved to date.